Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Autor: S Ghosh, M Long, E Ott, C Gasink, T Baker, B Godwin, Y Miao, E Loftus

Publikováno v: Journal of Crohn's and Colitis. 17:i681-i682

Background Ustekinumab (UST) is an approved treatment for adults with inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]), psoriasis (PsO), and psoriatic arthritis (PsA). Here, we present pooled safety analyses in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d368efbc5942043c3ce40bb1ce624c14
https://doi.org/10.1093/ecco-jcc/jjac190.0683

Zobrazit plný text záznamu

OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Autor: S Ghosh, B Feagan, E Ott, C Gasink, C Marano, Y Miao, W Sandborn, S Danese, M Abreu, B Sands

Publikováno v: Journal of Crohn's and Colitis. 17:i55-i56

Background Long-term efficacy of ustekinumab (UST) has been reported in Crohn’s disease (CD) through 5 years (yrs)1 and in ulcerative colitis (UC) through 4 yrs.2 A previous pooled analysis of long-term safety data reported a favorable UST safety t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f55e2c25a0fc4e6cec548a3d1e55be98
https://doi.org/10.1093/ecco-jcc/jjac190.0039

Zobrazit plný text záznamu

P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

Autor: J Panés, R Panaccione, B Sands, C Gasink, C Marano, T Ma, T Hoops

Publikováno v: Journal of Crohn's and Colitis. 17:i706-i707

Background Remission off steroids is a major treatment goal in inflammatory bowel disease. In the recent CORE-IBD consensus,1 the preferred definition of “corticosteroid-free” remission in clinical trials was withdrawal ≥12 weeks before the ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e9fb9fca323e3840bbae947543a9b96
https://doi.org/10.1093/ecco-jcc/jjac190.0708

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis

Autor: S Danese, S B Hanauer, V Jairath, E Mihaly, R Vicente Lidón, E Ott, C Gasink, Y Miao, T Ma, C Marano, B E Sands

Publikováno v: Journal of Crohn's and Colitis. 16:i434-i435

Background Ustekinumab (UST) is an approved biologic for the treatment of adults with inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]). Previously, an integrated analysis of safety data through up to 5 years (yrs)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f18944ea9b187881906fba5afabfc662
https://doi.org/10.1093/ecco-jcc/jjab232.584

Zobrazit plný text záznamu

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

Autor: M Allez, J D Lewis, S B Hanauer, S Danese, P M Irving, C Gasink, T Hoops, J L Izanec, T Ma, E V Loftus, E J Scherl, R Panaccione, W J Sandborn, B E Sands

Publikováno v: Journal of Crohn's and Colitis. 16:i379-i380

Background Entry criteria and outcome measures of Crohn’s disease (CD) clinical trials have evolved. Patients are now required to have active inflammation on screening endoscopy, with some studies requiring moderate-severe SES-CD scores. Recent tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa7e758d8f8fa42764d6e5cccdf7201e
https://doi.org/10.1093/ecco-jcc/jjab232.504

Zobrazit plný text záznamu

P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials

Autor: L Peyrin-Biroulet, R Panaccione, C Gasink, T Hoops, J L Izanec, T Ma, M Nazar, I Bravata, M Lahaye, P M Irving, E V Loftus, S Danese, B E Sands

Publikováno v: Journal of Crohn's and Colitis. 16:i460-i460

Background Perianal fistulas are common and cause significant quality of life impairment in patients (pts) with Crohn’s disease (CD). In previous phase 2/3 studies, ustekinumab (UST) showed some evidence of efficacy on fistula resolution, with no c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab8ee283cefc9e56ffa5c1106819ed90
https://doi.org/10.1093/ecco-jcc/jjab232.622

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání